恩替卡韦联合苦参素治疗HBeAg阳性慢性乙型肝炎的疗效观察  

Clinical effect of Entecavir combined with Oxymatrine on patients with HBeAg positive chronic hepatitis B

作　　者：邵志林[1] 张炳煌[1,2] 

机构地区：[1]黄石市中医院肝病科,湖北黄石435000 [2]湖北中医学院

出　　处：《中国中西医结合消化杂志》2010年第2期92-94,共3页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

摘　　要：[目的]观察恩替卡韦(ETV)联合苦参素治疗HBeAg阳性慢性乙型肝炎(CHB)的疗效。[方法]92例HBeAg阳性CHB患者随机分为2组,治疗组48例,每天服用ETV 0.5 mg,苦参素片0.6 g;对照组44例,每天服用ETV 0.5 mg。分别观察服药12、24、48周时的治疗效果。[结果]对照组和治疗组在12、24、48周的HBV DNA阴转率分别为29.55%、40.91%、63.64%和43.75%、58.33%、83.33%,2组比较在12、24周时差异无统计学意义(P>0.05),而在48周时差异有统计学意义(P<0.05)。对照组和治疗组的HBeAg转阴率,在12、24周时分别为36.37%、43.75%和50.00%、64.59%,2组比较P>0.05,而在48周时分别为59.09%和81.25%(P<0.05)。对照组和治疗组的HBeAg/HBeAb血清转换率,12、24周时分别为29.55%、37.50%和40.91%、52.09%,2组比较P>0.05,而在48周时分别为47.73%和68.75%,差异有统计学意义(P<0.05)。[结论]ETV联合苦参素治疗CHB可明显提高抗病毒治疗效果。[Objective]To observe the effects of Entecavir combined with oxymatrine on patients with HBeAg-positive chronic hepatitis B（CHB）.[Methods]Ninety-two cases were enrolled with HBeAg-positive CHB.They were randomly divided into treatment group（48 cases）and control group（44 cases）,patents in treatment group daily received Entecavir 0.5 mg,Oxymatrine tablets 0.6 g and those in control group daily doses Entecavir 0.5 mg.Therapeutic effect was observed in 12,24,48 weeks after medication.[Results]The HBV-DNA negative conversion rates in control group and treatment group after 12,24,48 weeks were 29.55%,40.91%,63.64% and 43.75%,58.33%,83.33%,respectively,and in the 12,24 weeks,no statistically significant difference was found between two groups（P〉0.05）,while in 48 weeks there was significantly difference between them（P〈0.05）.The HBeAg seroconversion rates of control group and treatment group in 12 weeks and 24 weeks were respectively 36.37%,43.75% and 50.00%,64.59%,there was no significant difference between two group（P〉0.05）,while in 48 weeks,respectively 59.09% and 81.25%,a significant difference was found（P〈0.05）.The HBeAg / HBeAb seroconversion rate of control group and treatment group in 12 weeks and 24 weeks were respectively 29.55%,37.50% and 40.91%,52.09%（P〉0.05）,while in 48 weeks,respectively 47.73 % and 68.75%.The differences were also statistically significant（P〈0.05）.[Conclusion]The combination of Entecavir and Oxymatrine can significantly enhance the effectiveness of anti-viral therapeutic in the treatment of CHB.

关 键 词：乙型肝炎 慢性 乙型肝炎核心抗原 恩替卡韦 苦参素 

分 类 号：R512.62[医药卫生—内科学]